Open AccessHydroxyzine revealing acquired neuromuscular weakness in a patient with COVID-19 disease
Author(s) -
Mohamed Bahi,
Y. Aissaoui,
Ayoub Belhadj,
Youssef Qamouss,
Rachid Seddiki
Publication year - 2021
Publication title -
the southwest respiratory and critical care chronicles
Language(s) - English
Resource type - Journals
ISSN - 2325-9205
DOI - 10.12746/swrccc.v9i40.875
Subject(s) - ards , hydroxyzine , medicine , weakness , antihistamine , anesthesia , neuromuscular disease , muscle weakness , respiratory failure , covid-19 , respiratory distress , intensive care medicine , disease , surgery , lung , infectious disease (medical specialty)
Acquired neuromuscular weakness often develops in patients with an acute respiratory distress syndrome (ARDS), in particular in patients who are ventilated and sedated for long periods. This has been rarely described in the literature on ARDS secondary to SARS-CoV-2 infection. Our clinical case revealed the existence of these neuromuscular manifestations in the COVID-19 disease after the use of hydroxyzine, an antihistamine whose respiratory side-effects are unknown.
Keywords: Neuromuscular weakness, COVID-19, hydroxyzine, hypercapnia.